文献速递妇科肿瘤

PROFAST试验:高级别复杂晚期卵巢癌手术实施加速康复外科的随机试验

PROFAST: A randomised trial implementing enhanced recovery after surgery for highcomplexity advanced ovarian cancer surgery.
PubMed 文献 · Eur J Cancer · 2020-07-18

PROFAST是一项前瞻性随机临床试验,在西班牙巴塞罗那妇科肿瘤参考医院纳入疑似或确诊晚期卵巢癌并接受手术的女性,比较ERAS方案与常规管理方案。结果显示ERAS组中位住院时间减少2天(7天 vs 9天,p=0.0099),再入院率降低(6% vs 20%,p=0.0334),且未增加并发症或死亡率。

要点

  • ERAS组中位住院时间较常规管理组减少2天(7 vs 9天,p=0.0099)。
  • ERAS组再入院率显著低于常规管理组(6% vs 20%,p=0.0334)。
  • 两组术中/术后并发症、严重并发症、再手术及死亡率无显著差异。

核心结论

  • 晚期卵巢癌患者实施ERAS方案可缩短住院时间并降低再入院率,且不增加并发症或死亡率。

研究设计与样本

  • 前瞻性、干预性随机临床试验,在西班牙巴塞罗那妇科肿瘤参考医院开展,2014年6月至2018年3月招募110例,排除11例后ERAS组50例、常规管理组49例。

主要发现

  • 两组基线特征和肿瘤细胞减灭术复杂度可比,总体中/高Aletti手术复杂度评分为7.4,ERAS方案总体依从性为92%。
  • ERAS组较常规管理组中位住院时间减少2天(7 vs 9天,p=0.0099),再入院率降低(6% vs 20%,p=0.0334)。
  • 术中或术后并发症发生率、严重(Clavien-Dindo IIIB-IV级)并发症、综合并发症指数、初次住院期间再手术或死亡率均无显著差异。

临床怎么用

  • 对于中/高复杂度的晚期卵巢癌肿瘤细胞减灭术,ERAS应作为标准实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Enhanced recovery after surgery (ERAS) programs include multiple perioperative elements designed to achieve early recovery after surgery and a shorter length of stay (LOS) in hospital. The PROFAST trial aimed to expand the evidence base for implementing ERAS in advanced gynaecologic oncology surgery. METHODS: This prospective, interventional randomised clinical trial enrolled women undergoing surgery for either suspected or diagnosed advanced ovarian cancer, at a reference hospital in gynaecologic oncology in Barcelona (Spain) and who were treated after either an ERAS protocol or conventional management (CM) protocol. All enrolled women who underwent cytoreductive surgery were included in the primary analysis. The primary outcome was reduction in LOS, and secondary outcomes were incidence and type of intraoperative and postoperative complications, rate of readmission and mortality within a 30-d follow-up period. This trial is registered at ClinicalTrials.gov, number NCT02172638. FINDINGS: From June 2014 to March 2018, 110 women were recruited, of which eleven were excluded. The ERAS group comprised 50 patients, and the CM group, 49 patients. Both groups were comparable with respect to baseline characteristics and complexity of the cytoreductive surgery, with an overall medium/high Aletti surgical complexity score of 7.4. Overall compliance to the ERAS protocol was 92%. As compared with the patients in the CM group, patients in the ERAS group had a decreased median of LOS of two days (7 versus 9 days; p = 0.0099) and a decreased rate of readmission (6% versus 20%, p = 0.0334). No further significant differences were detected with respect to incidence of intraoperative or postoperative complications, severe (Clavien-Dindo grade IIIB-IV) complications, Comprehensive Complication Index, reoperation during primary stay, or mortality. INTERPRETATION: Patients with advanced ovarian cancer in the ERAS program had a decreased LOS and decreased rate of readmission as compared with those in CM, with no increased morbidity or mortality. This study provides important evidence for the benefits of ERAS management even for gynaecologic surgeries of medium/high complexity and suggests that ERAS should be a standard practice for cytoreductive surgeries for peritoneal carcinomatosis.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Sánchez-Iglesias JL, Carbonell-Socias M, Pérez-Benavente MA, et al. PROFAST: A randomised trial implementing enhanced recovery after surgery for highcomplexity advanced ovarian cancer surgery. Eur J Cancer. 2020. PMID: 32688208. doi:10.1016/j.ejca.2020.06.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。